In Vitro Susceptibility Testing of Eravacycline Is Unaffected by Medium Age and Nonstandard Assay Parameters | Zendy

Trudy H. Grossman | Zendy; Chris M. Pillar | Zendy; Daniel F. Sahm | Zendy; Joyce A. Sutcliffe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Susceptibility Testing of Eravacycline Is Unaffected by Medium Age and Nonstandard Assay Parameters

Author(s) -

Trudy H. Grossman,

Chris M. Pillar,

Daniel F. Sahm,

Joyce A. Sutcliffe

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.04727-14

Subject(s) - antibiotics , microbiology and biotechnology , urinary system , biology , medicine

Eravacycline is a fluorocycline antibiotic in phase 3 clinical development for complicated intra-abdominal and urinary tract infections. To support its clinical development, a study was conducted to evaluate the effects of various susceptibility test parameters on the MIC values for aerobic bacteria. The results showed that eravacycline appears to be largely unaffected by medium age, medium additives, and other nonstandard assay conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research